Last reviewed · How we verify
XaraColl — Competitive Intelligence Brief
marketed
Bioabsorbable hemostatic and antimicrobial wound matrix
Chlorhexidine (broad-spectrum antimicrobial); collagen matrix (hemostatic scaffold)
Surgery/Wound Management
Small molecule
Live · refreshed every 30 min
Target snapshot
XaraColl (XaraColl) — Innocoll. XaraColl is a bioabsorbable collagen matrix that delivers chlorhexidine locally to promote hemostasis and reduce infection in surgical wounds.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| XaraColl TARGET | XaraColl | Innocoll | marketed | Bioabsorbable hemostatic and antimicrobial wound matrix | Chlorhexidine (broad-spectrum antimicrobial); collagen matrix (hemostatic scaffold) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Bioabsorbable hemostatic and antimicrobial wound matrix class)
- Innocoll · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- XaraColl CI watch — RSS
- XaraColl CI watch — Atom
- XaraColl CI watch — JSON
- XaraColl alone — RSS
- Whole Bioabsorbable hemostatic and antimicrobial wound matrix class — RSS
Cite this brief
Drug Landscape (2026). XaraColl — Competitive Intelligence Brief. https://druglandscape.com/ci/xaracoll. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab